2-Fluorodeoxyarbutin, a derivative of Deoxyarbutin, is a tyrosine hydroxylase and dopa oxidase inhibitor. 2-Fluorodeoxyarbutin inhibits melanin synthesis in intact melanocytes. 2-Fluorodeoxyarbutin can be used for the strudy of skin lightening or for ameliorating hyperpigmented lesions.

SB-583355 (Compound 56) is a potent G2A antagonist. SB-583355 can be prepared by a Suzuki reaction between 4-methoxyphenyl boronic acid and 3-bromo-4-hydroxybenzoic acid following the conditions followed by an amide coupling reaction. SB-583355 blocks the activation of G2A mediated either by 9-HOPE or T-10148 in human G2A expressing CHO-K1 cells. SB-583355 can be studied in research for inflammation, myeloid leukemia, and neuropathic pain.

HEAL-116 is a potent, specific and orally active 3β-hydroxysteroid dehydrogenase type 1 (3βHSD1) inhibitor with an IC50 of 1.18 μM and a KD of 1.32 μM. HEAL-116 inhibits DHEA metabolism and DHEA-induced target gene expression and cell proliferation. HEAL-116 can be used for cancer research, such as prostate cancer.

SMARCA2 Ligand-Linker Conjugate-4 is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for SMARCA2 and a PROTAC linker, which recruits E3 ligases. SMARCA2 Ligand-Linker Conjugate-4 can be used for synthesis of PROTAC SMARCA2 degrader-35.

Votoplam (PTC518) hydrochloride is an HTT gene regulator with an IC50 ≤ 0.1 μM. Votoplam hydrochloride can be used in the research of Huntington's disease.

Faridoxorubicin (AVA-6000) is a prodrug targeting fibroblast activation protein α (FAPα). Faridoxorubicin releases active doxorubicin through FAPα-mediated cleavage, enhancing intratumoral drug exposure and reducing cardiac toxicity. Faridoxorubicin is promising for research of solid tumors (e.g., colorectal cancer liver metastasis).

Copper ionophore I is an efficient copper ion carrier. Copper ionophore I can regulate various intracellular copper levels to induce cuproptosis, such as 4T1 (IC50 = 0.45 μM) and MDA-MB-231(IC50 = 1.21 μM) cells. Copper ionophore I can induce an increase in ROS and cause mitochondrial dysfunction. Copper ionophore I can reduce the expression of FDX1, DLAT, and LIAS proteins. Copper ionophore I can activate immune related pathways and promote T cell infiltration. Copper ionophore I can be used for cancer research.

RPR107393 is an orally active potent selective squalene synthase (SQS) inhibitor. RPR107393 inhibits rat liver microsomal squalene synthase with an IC50 value of 0.8 nM. RPR107393 reduces triglyceride biosynthesis by suppressing fatty acid biosynthesis via an increase in intracellular farnesol and its derivatives. RPR107393 reduces plasma cholesterol in rats and marmosets. RPR107393 can be used for metabolic disease research, such as hypercholesterolemia, hypertriglyceridemia and atherosclerosis[1][2].

D4-Ribavirin (Compound 4) is a deoxygenated ribavirin analogue. D4-Ribavirin has antiviral property in vitro against the RNA-containing bunyaviruses–Rift Valley Fever () with an IC50 of 61 μg/mL.

C2 Adamantanyl globotriaosylceramide (d18:1/2:0) (AdaGb3), a water-soluble globotriaosylceramide analog, is a bioactive sphingolipid. C2 Adamantanyl globotriaosylceramide (d18:1/2:0) reverses MDR1-MDCK cell drug resistance. C2 Adamantanyl globotriaosylceramide (d18:1/2:0) has high affinity for verotoxin (VT).

MDL-25637 is an α-glucosidase inhibitor. MDL-25637 can inhibit the activity of sucrose enzyme, maltase, isomaltase, glucose amylase, and trehalose in the intestinal tract of rats. MDL-25637 can be used in the research of diabetes.

C2 Adamantanyl galactosylceramide (AdaGalCer) (d18:1/2:0) is a bioactive sphingolipid. C2 Adamantanyl galactosylceramide (d18:1/2:0) stimulates glucocerebrosidase activity in vitro. C2 Adamantanyl galactosylceramide (d18:1/2:0) inhibits microsomal LacCer and Gb3 synthase, and inhibits cell sulfatide synthesis. C2 Adamantanyl galactosylceramide (d18:1/2:0) reduces glucosylceramide (GlcCer) levels in normal and lysosomal storage disease (LSD) cells. C2 Adamantanyl galactosylceramide (d18:1/2:0) acts as a substrate for A4GALT and is able to lower Gb3 levels with an IC50 concentration of 40 μM in fabry disease cells.

CKD-711 is an orally active aminooligosaccharide α-glucosidase inhibitor with an IC50 of 78 μg/mL. CKD-711 also inhibits porcine intestinal maltase and sucrose with IC50 values of 2.5 and 0.5 μg/mL. CKD-711 shows selective antibacterial activity against Comamonas terrigena. CKD-711 can be used for the researches of infection and metabolic disease, such as diabetes.

ZN148 is a zinc-chelating synthetic metallo-β-lactamase (MBL) inhibitor which attenuates MBL-mediated carbapenem resistance. ZN148 can restore the in vitro clinical susceptibility to carbapenems in >98% of a large international collection of MBL-producing clinical Enterobacterales strains. ZN148 can be utilized in research on anti MBL-producing bacteria.

3-Deoxy-3-fluoro-D-fructose (Compound 12) is a derivative of 2,5-Anhydro-D-mannitol. 3-Deoxy-3-fluoro-D-fructose is a selective probe of Hexose transporter 5 (GLUT5). 3-Deoxy-3-fluoro-D-fructose inhibits the transport of D-fructose labeled with 14C by GLUT5 with IC50s of 1.16 and 2.37 µM in EMT-6 and MCF-7 cells. 3-Deoxy-3-fluoro-D-fructose can be used for positron emission tomography (PET) imaging of cancers.

C16 Ceramide (Cer) (d18:1(14Z)/16:0) is a sphingosine ceramide composed of long-chain sphingosine (d18:1) and palmitic acid (C16:0). It is one of the key lipid signaling molecules involved in apoptosis signaling. C16 ceramides are particularly involved in cell cycle arrest, cell death, and insulin signaling inhibition.

5-C-phenethyl-DNJ (hydrochloride) is an orally active acid α-glucosidase (GAA) activator. 5-C-phenethyl-DNJ (hydrochloride) can increase GAA activity in various tissues, particularly in the diaphragm. 5-C-phenethyl-DNJ (hydrochloride) can be used for the research of metabolic disease, such as Pompe disease.

Mc-Lys(PEG12)-Cap-Ala-Ala-PABC is a linker of MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan.

SDNUM04 is a C-X-C chemokine receptor 4 (CXCR4) ligand and can be used as a tracer in tumor-targeting studies.

MC-GGFG-NH-CH2-O-propionic acid is a ADC linker that can be used in the synthesis of LM-D01.

UNC3133 (Compound 16) is a selective and orally active macrocyclic mer tyrosine kinase (MerTK) inhibitor with an IC50 of 8.1 nM. UNC3133 has certain selectivity towards the TAM family (Axl and Tyro3) (with a selectivity of approximately 7 times for Axl and about 10 times for Tyro3), and has similar inhibitory activity towards Flt3. UNC3133 exhibits anti-tumor and anti-infection activities.

UNC10088 is a molecular glue targeting NSD2. UNC10088 mediates the formation of a stable ternary complex between SCFFBXO22 and the NSD2 PWWP1 domain. UNC10088 promotes ubiquitination of the SCFFBXO22-dependent NSD2 PWWP1 domain through reversible covalent bonding with the C326 region of FBXO22. UNC10088 could be used in cancer research.

DTS-201 (CPI-0004) is a peptidic prodrug of Doxorubicin). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer.

NAA-004 is a novel azo compound formed by linking 5-aminosalicylic acid and 4-aminophenylacetic acid through an azo bond. NAA-004 has oral activity. NAA-004 can inhibit colon damage, intracavitary fluid accumulation, and MPO activity. NAA-004 can be used for research on colitis.

GLY-230 is an orally active compound. GLY-230 can inhibit nonenzymatic glycation and reduce glycated albumin. GLY-230 can reduce brain Aβ42 levels. GLY-230 can be used for the researches of metabolic and neurological disease, such as diabetic renal dysfunction.

Psa-AR is a PROTAC degrader targeting PSMA. Psa-AR exhibits potent degradation ability of AR, AR-V7, and HSP90, and induces cell apoptosis. Psa-AR can be used for cancer research.

Butanixin (2-[(4-Butylphenyl)amino]-3-pyridinecarboxylic acid) is a cyclooxygenase (COX) inhibitor. It exerts anti-inflammatory and analgesic activity by reducing prostaglandin production. It is used in the research of musculoskeletal disorders.

Gemigliptin (LC15-0444 ) tartrate hydrate is a selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate hydrate exhibits potent anti-glycation properties. Gemigliptin tartrate hydrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications.

Boc-VC-PAB-MMAF is a linker that can be synthesized to antibody-drug conjugate (ADC). Boc-VC-PAB-MMAF can be used for the study of cancer.

RG-239 is an orally active TGR5 agonist with an EC50 of 120 nM, significantly outperforming Betulinic acid (EC50 = 1.04 μM). RG-239 demonstrates higher selectivity for TGR5 compared to the FXRα. RG-239 increases mitochondrial activity in adipocytes and promotes neurite outgrowth at higher concentrations. RG-239 inhibits LPS-induced iNOS expression and nitrite production in Raw264.7 and microglia cells. RG-239 can be used for the study of type 2 diabetes.